When the Trump administration accused China of “unfairly” using venture capital to acquire technologies last month, it singled out the firm 6 Dimensions Capital, calling it a suspicious agent of the Chinese government bent on acquiring U.S. biotechnology.

That came as a surprise to 6 Dimensions’ CEO, Leon Chen, who said neither he nor anyone at his firm had ever been contacted by the U.S. trade representative, which issued the report naming his firm.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy